← FDA Drug Approvals (Drugs@FDA)

CABAZITAXEL

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: BRECKENRIDGE · Approved 2022-06-23

Drug application

FDA Application #

ANDA207619

Application type

Abbreviated New Drug Application (Generic)

Brand name

CABAZITAXEL

Generic name

Cabazitaxel

Active ingredients

CABAZITAXEL

Dosage form

SOLUTION

Route

INTRAVENOUS

Marketing status

Discontinued

Sponsor

BRECKENRIDGE

First approval

2022-06-23

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown